Exelixis, Inc. (NASDAQ: EXEL) today announced that it is initiating COSMIC-313, a phase 3 pivotal trial of cabozantinib (CABOMETYX®) in ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Corporate News FDA Management Comments

Exelixis (EXEL) PT Lowered to $25 at CowenMay 2, 2019 8:48 AM Exelixis (EXEL) Tops Q1 EPS by 4cMay 1, 2019 4:55 PM Exelixis Initiating Phase 3 Pivotal Trial (COSMIC-313) of Cabozantinib in Combination with Nivolumab and Ipilimumab Versus Nivolumab and Ipilimumab in Previously Untreated Advanced Renal Cell CarcinomMay 1, 2019 4:06 PM